CXCL10 and neoplasm: However, the average expression of CXCL10 and CXCL9 was higher in Group 2 tumors by 22.8-fold and 12.3-fold, respectively (Figure 3B), which supports the idea that Group 2 tumors were “immune-active”, which may have resulted in a PD-1 positive tumor immune environment.